Abstract: The present invention relates to a dual activity domain of JAK proteins, namely JH2. It is provided that the JH2 domain is a true and important target for drug development, especially for diseases caused by aberrant JAK signalling, such as myeloproliferative disorders and leukemias.
Abstract: The present invention relates to a dual activity domain JAK proteins, namely JH2. It is provided that the JH2 domain is a true and important target for drug development, especially for diseases caused by aberrant JAK signalling, such as myeloproliferative disorders and leukemias.